Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
Abeona Therapeutics Inc. filed a current report to share that it has prepared an updated investor presentation. The company plans to use this presentation in meetings with investors, analysts, and other interested parties.
The investor presentation, dated June 10, 2026, is furnished as Exhibit 99.1 under Regulation FD. Abeona notes that this material is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O’Malley reported small stock sales primarily to cover taxes on vested awards. He sold 4,826 shares of common stock at a weighted average price of $5.4295 on June 8, 2026 and 6,305 shares at $5.3042 on June 9, 2026, totaling 11,131 shares. A footnote states the sales were made to cover tax obligations from vesting of restricted stock awards. After these transactions, he directly owned 440,003 shares of Abeona common stock.
Abeona Therapeutics’ Chief Financial Officer Joseph Walter Vazzano reported selling a total of 49,338 shares of common stock in open-market transactions on June 8–9, 2026 at weighted average prices around $5.30–$5.43 per share. According to the disclosure, these sales were made to cover tax obligations arising from the vesting of restricted stock awards and were carried out under a Rule 10b5-1 trading plan adopted on January 21, 2026. Following the transactions, Vazzano directly holds 518,437 shares of Abeona Therapeutics common stock.
Abeona Therapeutics’ Chief Commercial Officer Madhav Vasanthavada reported small stock sales primarily for tax purposes. On June 8, he sold 4,170 shares of common stock in open-market transactions at a weighted average price of $5.4295 per share. On June 9, he sold another 5,450 shares at a weighted average price of $5.3042 per share. A footnote explains that these sales were made to cover tax obligations tied to the vesting of restricted stock awards, indicating they are compensation-related rather than discretionary portfolio trades. After these transactions, he directly held 303,451 shares of Abeona common stock.
Abeona Therapeutics CEO Vishwas Seshadri reported selling a total of 56,344 shares of common stock in open-market transactions on June 8 and 9, 2026. According to the disclosure, these sales were made to cover tax obligations associated with the vesting of restricted stock awards.
After these tax-related sales, Seshadri directly owns 1,374,079 shares of Abeona Therapeutics common stock.
ABEO submitted a Rule 144 notice reporting recent dispositions of Common Stock by Joseph Vazzano. The filing lists a sale of 785 shares on 03/16/2026 for $3,737.00 and a sale of 13,421 shares on 06/08/2026 for $71,188.00.
The notice also references Common Stock and Restricted Stock Awards and includes numeric entries of 25,646 and 51,747 in related sections of the form.
ABEO reported a proposed sale of 10,000 shares of Common Stock via Stifel Nicolaus & Company Inc. The filing lists a trade date or filing date of 06/08/2026 and identifies Restricted Stock Awards of 21,334 shares in the securities section. The record shows a prior sale by Madhav Vasanthavada of 5,548 shares on 05/11/2026 for $33,073.00.
ABEO submitted a Form 144 notice reporting a proposed sale of 112,276 shares of Common Stock tied to Restricted Stock Awards, dated 06/05/2026 with an effective filing date of 06/08/2026.
The filing also reports prior transactions: Vishwas Seshadri sold 29,958 shares on 03/31/2026 with an aggregate reported value of $131,363.00. The filing is an SEC notification of proposed resale under equity compensation rules.
ABEO submitted a Form 144 notice reporting a proposed sale of 25,000 shares of Common Stock through Stifel Nicolaus & Company Inc. The filing also lists 51,747 Restricted Stock Awards and indicates an earlier reported sale of 785 shares for $3,737.00 on 03/16/2026. The transaction dates shown include 06/05/2026 and 06/08/2026.